MICRODOSING

Our microdosing clinical trials are a world first! We have the regulatory approvals for take-home microdosing MB22001, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for take home use in our clinical trials

Emerging Treatments in Mental Health

Microdosing involves the repeated administration of small sub-hallucinogenic doses of psychedelic medicines which are believed to have significant impact on improvements in mood, creativity, happiness and energy. Results from Phase 1 clinical trials microdosing MB22001 showed statistically significant improvements in mood, including “happiness”, “wellness”, “social connectivity”, “creativity” and “energy”. These results are exciting for our continuation Phase 2 microdosing clinical trials in patients suffering from Major Depressive Disorder (MDD). MB22001 is a promising agent for treating MDD.

bottles of liquid in a lab

MICRODOSING (MB22001) is potentially a globally scalable and affordable solution to using psychedelic medicines to treat mental health conditions in medical practice. Our Phase 1 and Phase 2 take-home clinical trials have shown the drug can be taken safely and effectively by patients out in the community, at home and then get on with their day with minimal disruption.